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Abstract
Laromustine is a chemotherapeutic sulfonylhydrazine prodrug used in clinical trials
against acute myeloid leukemia. Though laromustine showed some success in clinical trials,
more experiments are needed to understand the hematological toxicity and the molecular
mechanisms of patients’ resistance. This project aims to develop a strategy to identify
compounds synergistic with laromustine in cultured leukemia cells from a library of 450
FDA-approved compounds through a forward chemical genetic screen. To optimize the
screen, the cell seeding density, doubling time, and dose response curves were determined.
The optimized concentration of HL60 cells in these experiments was determined to be
between 25,000 and 40,000 cells/well in 384 well-plates for 12 or 24 hr before the
measurement. The LD50 of laromustine was determined to be 159 µM. A concentration of 50
µM was identified as optimal for the chemical genetic screen because when tested with
temozolomide, a compound with a similar mechanism of action to laromustine, 50 µM
laromustine and 500 µM temozolomide showed synergistic effects. Following those
optimized conditions, the chemical genetic screen should have the potential to find
compounds that enhance laromustine’s cytotoxicity, which, in the future, would help identify
new molecular targets for laromustine’s mechanism of action.
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Introduction
Acute myeloid leukemia (AML) is the most common type of acute leukemia, which is
a type of fast-growing cancer of the blood and bone marrow.1 According to NCI’s PDQ cancer
information summary, patients with this type of cancer have abnormal myeloblasts, red
blood cells, or platelets. Those myeloid blasts cannot become healthy white cells, and when
abnormal cells build up in the bone marrow, less room remains for the healthy cells.2 AML is
a disease that primarily affects elderly patients with a median age of presentation at around
68 years old.3 The standard of care treatment for AML typically involves chemotherapy,
radiation therapy, or stem cell transplant. Among these, chemotherapy is the most common
method to treat AML patients.
Laromustine

(cloretazine;

1,2-

bis(methylsulfonyl)-1-(2-chloroethyl)-2-

[(methylamino) carbonyl]hydrazine) is a chemotherapeutic sulfonylhydrazine prodrug used
in clinical trials against AML. Laromustine is a prodrug because the compound is not
pharmacologically active until it decomposes into its active forms. Laromustine generates
two reactive electrophiles, methyl isocyanate and 90CE, by base catalysis, as shown in Figure
1.4

Figure 1: Decomposition of laromustine to 90CE and methyl isocyanate.4
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Both species have critical functions, but the in situ mechanisms and features of 90CE
have been studied the most. When laromustine yields its two active subspecies, 90CE is
responsible for 2-chloroethylation activity on DNA at the O6 position of guanine (Figure 2).5
The subsequent formation of an inter-strand crosslink with cytosine is believed to be the
reason that laromustine can stop the DNA replication and thus the proliferation of AML and
glioblastoma multiforme (GBM) cancer cells4,6.

Figure 2. The 90CE 2-chloroethylation and the formation of the interstrand crosslink. (The
orange box highlights the 2-chloroethylation activity at the O6 position of guanine.)
A particular Phase I study demonstrated that laromustine had significant
antileukemic activity towards refractory leukemia patients. In this study, laromustine was
combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C). However, some
patients did not respond to this compound. The activity of O6-alkylguanine-DNA
alkyltransferase (AGT) might be a predictor of responsiveness to laromustine.7 A study by
Finch et al. also discusses this possibility. In their study, they found that cells with high AGT
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expression prevented the formation of the cross-links by transferring the alkyl adduct from
guanine to a cysteine moiety in the protein.8 In this situation, AGT is serving as a DNA repair
protein, and its existence in tumor tissues affects the effectiveness of the chemotherapeutic
drugs.
According to another phase II clinical study, laromustine has significant success in
treating elderly patients with poor-risk AML.9 Though some progress was observed by an
increase in the survival for those patients who were able to respond to this treatment,
hematological side effects, such as myelosuppression, were detected in patients.9 The study
suggested further studies using a combination of laromustine with standard treatment
regimens. It remains challenging for scientists to decide whether laromustine should be part
of the treatment of AML.
A very recent study by Penketh et al. compared the combined treatment with
chloroethylating and carbamoylating prodrugs with laromustine.10 This study demonstrates
an excellent tumor selectivity of laromustine. Another recent analysis by Nassar et al.
conducted a pharmacokinetic analysis of laromustine. This study estimates that the mean
volume of distribution at steady state exceeds the amount of the total body water, which
means that laromustine has distributed to the peripheral tissues. Also, laromustine has a
short half-life, less than an hour, which reveals a rapid clearance.11 Following to the insights
brought by those two studies, further experiments are in need to improve the performance
of laromustine. The phase II study previously mentioned specifically suggested to combine
laromustine with other drugs.12
Based on the suggestions from the clinical trials, this project attempts to identify
compounds synergistic with laromustine in cultured leukemia cells. This study is first going
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to access the combined effects of laromustine with temozolomide (TMZ). TMZ is another
compound used clinically against GBM, which is one of the most aggressive brain cancers,
and TMZ targets the same position on DNA as laromustine. It functions through O6 guanine
methylation, which differs from the chloroethylation and crosslinking activity of
laromustine.13 Methylation of O6 guanine triggers mismatch-repair mechanisms and can lead
to cytotoxicity.14 Moreover, TMZ can deplete AGT in tumor tissue and peripheral blood
mononuclear cells, which is thought to occur via irreversible methyl transfer to AGT from
TMZ-methylated guanine O6.15–17 Therefore, this study hopes to observe that TMZ increases
laromustine’s cytotoxicity against cultured cancer cells by depleting AGT.
Besides temozolomide, this project is also going to test the combined effect between
laromustine and Olaparib. Olaparib is a poly-(ADP-ribose) polymerase (PARP) inhibitor,
which was approved by the FDA in the treatment of BRAC1 or BRAC2 mutated ovarian
cancer and HER2-negative metastatic breast cancer. PARP is an enzyme involved in DNA
repair processes, particularly base excision repair.18 Due to Olaparib’s ability to inhibit DNA
damage repair, research has demonstrated that the combination of chemotherapy and PARP
inhibition may benefit PARP1 SNP rs1805407 (single nucleotide polymorphism) carriers
(especially in ovarian cancers).19 Consider the results shown by the combination of
chemotherapy and PARP inhibition, this project is also going to test the combination of
laromustine and Olaparib, which should increase laromustine’s cytotoxicity.
Finally, this experiment sought to identify new molecular targets for laromustine’s
mechanism of action by testing compounds from a library of 450 US Food and Drug
Administration (FDA) approved drugs using a forward chemical genetic screen. A chemical
genetic screen would be able to conduct in the future when all the screening conditions are
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optimized, and Figure 3 shows its basic schematic. Different from a genetic screen or
mutagenesis, a chemical genetic screen uses small molecules to perturb biological processes,
testing hundreds of compounds simultaneously in a cell-based assay.20 A reverse chemical
genetic screen is usually a target-based approach, but a forward chemical genetic screen is a
phenotype-based approach.20 Forward chemical genetic screens have been successfully
applied in several fields. For instance, Child et al. performed a chemical genetic screen
against toxoplasma Gondii and identified compounds that significantly enhance infectivity,
which helped them understand the mechanisms under the induction of invasion.21

Figure 3. From a chemical genetic screen to drug discovery. A cell-based assay is
performed to figure out the compounds that can induce a particular cellular phenotype
(cell death for this project). Once the hits from the primary screen are identified and
validated, the cellular targets of those hits could be further analyzed by various genetic
assay.22
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In this experiment, the “phenotype” would be cell death, which means the
combination of a particular compound and laromustine induces more cell death as compared
to their effects individually. As shown in Figure 3, a forward chemical genetic screen usually
involves three stages. First, a primary screen identifies molecules of interest. In this case, this
screen should find compounds that can amplify laromustine’s cytotoxicity in this cellviability assay. Then, cellular targets that interact with the particular chemicals, which in
most cases are proteins, are identified.20 A common method to confirm those targets would
be an affinity pull-down assay using the protein that interacts with the isolated compounds.
This step could potentially suggest new molecular targets for laromustine’s mechanism of
action. Because the FDA-approved compounds have well-studied molecular pathways, they
are going to quickly bring insights into the new mechanism of laromustine’s action. The final
step consists of validation of the molecular targets, and characterization of their specificity
as small molecules usually show multiple but unrelated effects due to low specificity.20
According to the suggestions, to test the specificity of the target, a genetic test using a
modified cell line for the identified cellular target and a competition assay should be
applied.20
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Material and Methods
HL60 Cell Culture:
HL60 human acute myeloid leukemia cells were maintained between 1 x 105 and 8 x
105 cells/mL in Roswell Park Memorial Institute (RPMI) medium with 0.1% gentamycin, 1%
L-glutamine, and 10% fetal bovine serum. Cells were grown at 37°C with 5% CO2 and 100%
relative humidity. All incubations described herein are in these conditions unless specified
otherwise.

Determination of HL60 Optimum Seeding Concentration:
The optimum cell seeding concentration was determined by seeding cultured HL60
cells in triplicate at concentrations ranging from 156 cells/well to 40,000 cells/well (from 6
cells/µL to 1,600 cells/µL) in a 384-well plate (25µL/well). The negative controls lacked cells
with an equal volume of RPMI media. After 30 min, 25 µL of CellTiter-Glo reagent (CellTiterGlo Luminescent Cell Viability Assay, Promega, WI) was added to each well. The
luminescence signal was detected using a SpectraMax M5 plate reader (Molecular Devices)
after 10 min. Data were analyzed as the average luminescence by triplicates, and errors were
measured by the standard deviation.

Determination of HL60 Doubling Time and Maximum Cells per Well
The incubation time that HL60 cells needed to double themselves in a 384-well plate
was tested by seeding cultured HL60 cells in different concentrations. Initial cell
concentrations ranged from 2,000 – 10,000 cells/well and were compared to the negative
control wells without cells. 25 µL of CellTiter-Glo luminescent reagent was added to each
13

well at specified time points ending at 120 hr, then measured using the SpectraMax M5 plate
reader. Data were analyzed as the average luminescence, and errors were measured as
standard deviations.

Generation of Laromustine and Temozolomide Dose Response Curves
2,500 HL60 cells were seeded in 25 µL of RPMI at 25,000 cells per well in wells of a
384-well plate. Two-fold serial dilutions of laromustine and temozolomide were made in
DMSO with 4% DMSO and media as the controls. At 24 hr, 25 µL of the CellTiter-Glo reagent
was added to each well, and the relative luminescence signals were measured using the plate
reader. The best fit curve fit and LD-50 were generated by the Excel Solver tool, fit curve:
!
!"(

[%&'(&)*+] 2
)
-./0

.

Determination of Incubation Period of Temozolomide with Lethal Dose Treatment
HL60 cells were seeded in at 2,500 cells/well to determine the necessary exposure
time for temozolomide (TMZ) to result in cell death. Cells were treated with 2 mM of TMZ
and cellular viability was measured at indicated time points up to 24 hr using the CellTiterGlo assay as previously described. Positive control wells lacked TMZ but contained an
equivalent concentration of DMSO (4% w/v). Negative control wells contained only RPMI.

Verification of the Assay Optimization using Temozolomide
The conditions prepared for the chemical genetic screen were verified by testing
temozolomide for its synergism with laromustine. HL60 cells were seeded in the format of a
24-well plate with 1 x 106 cells/mL, 1 mL/well, and the cells were treated with various
14

combinations of laromustine and temozolomide. The control groups were treated with 2%
DMSO, laromustine alone, and temozolomide alone. After 12 or 24 hr, the cell mixtures in
each well were mixed by pipetting, then 25 µL of the mixture was transferred to wells of a
384-well plate. After 25 µL of the CellTiter-Glo reagent was added to each well, the
luminescence was measured using the plate reader. Data were analyzed for the average
luminescence and errors were measured by the standard deviation.
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Results
Optimal conditions for the high-throughput CellTiter-Glo assay are 40,000 cells/well incubated
for 24 hours prior to drug treatment
In order to give sufficient opportunity for HL60 cells to grow before drug treatment,
the optimal cell seeding concentration was determined. This optimal concentration should
not impede the growth of cells, and also this density should generate a stable luminescence
signal to measure. The best concentration is one that could generate a large light signal that
accurately reflects the different numbers of cells in each well. Cells were seeded in a
concentration ranging from 156 cells/well to 40,000 cells/well, and the signal was obtained
30 min after seeding (Figure 4). The seeding of 40,000 cells/well gave the largest
luminescence signal, just over 50,000 RLU and also had a significant difference from the
seeding of 20,000 cells/well. The concentrations ranging from 156 cells/well to 20,000
cells/well showed a relatively linear relationship between the concentration at seeding and
the luminescence signal.

Figure 4. Cells were seeded in concentration from 156 cells/well to 40,000 cells/well.
CellTiter-Glo reagent was added to each well 30 min later, and the signal was detected by
SpectraMax M5 (n=4).
16

In order to determine the time HL60 cells needed to multiply in 384-well plates, the
doubling time experiment was carried out. This experiment tried to observe the changes of
the cell growth from between 0 and 120 hr. According to Figure 5, the cells of different
concentrations generated stable signal before 24 hr. At 48 hr, huge error bars were observed,
so 48 hr would not be the ideal time point to take any measurement. To confirm this finding,
the same experiment was repeated, and the luminescence signal was detected over a longer
time period (0 – 120 hr). Cells grew in the first 48 hr (Figure 6) but were considered not
metabolically viable after that. After 48 hr, the number of cells reflected by the luminescence
signal was doubled, but with significant error. According to the previous experiments on this
project, laromustine results in significant loss of viability after 6 hr.23 Therefore,
measurements should take place 6 - 24 hr after the treatment. To make sure that cells yield
a significant luminescence signal with minimal error, a 24 hr incubation period for HL60 cells
was selected for this screen. This result is confirmed in Figure 7. After 24 hr, different
concentrations of cells provide significant amount of luminescence signals with only modest
error that can accurately represent the difference between different concentrations at
seeding.
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Figure 5. Determination of doubling time of HL60 cells. Wells were seeded with different
concentration of cells, and luminescence signal was detected from 0 to 48 hr (n=4).

Figure 6. Determination of doubling time of HL60 cells. Wells were seeded with different
concentration of cells, and luminescence signal was detected from 0 to 120 hr (n=4).
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Figure 7. Determination of doubling time of HL60 cells. Wells were seeded with different
concentration of cells, and luminescence signal was detected at 24 hr (n=4).
Temozolomide treatment results in significant loss of viability in HL60 cells after 24 hours.
When temozolomide enters cancer cells, cell death should be reflected in a change in
luminescence signal. The series of events will not happen immediately. The amount of time
for the drug to significantly impact cells must be experimentally determined.23 The viability
of HL60 cells was tested from between 0 and 48 hr post TMZ treatment with repeatable
results. In this experiment, HL60 cells showed a stable decrease in viability in the
experimental time frame. In the time trial experiment (Figure 8), the viability of HL60 cells
decreased from 0 to 24 hr.
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Figure 8. Determination of lethal dose time response of temozolomide using HL60 cells.
Data were collected from t = 0 to t = 48 hr. Data were analyzed for average luminescence by
quadruplicates, and error was measured by standard deviation (n=4).
The Median Lethal Dose of Laromustine in Treating HL60 cells is 159µM
When the HL60 cells were treated with laromustine at concentrations from 250 µM
to 2000 µM, HL60 cells lost most of their viability. When the cells were treated with 0.244
µM to 4 µM laromustine, most of the HL60 cells remained similarly viable to those of the
DMSO control group (Figure 8). The LD50 was calculated to be 159 µM. In order to test
laromustine’s synergistic effect with other compounds, a specific concentration needed to be
selected, such that most of the cells in the well would still be alive, but such that a slight
increase in the concentration of the drug would result in significant cell death. Laromustine
concentrations of 200 µM and 20 µM were selected as lethal and near-lethal doses,
respectively, for the further steps.
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Figure 9. The laromustine dose response curve for HL60 cells seeded at the concentrations
of 25,000 cells/well, in the format of 384-well plates. Concentrations of the drugs ranged
from 2000 µM to 0.24 µM in a two-fold serial dilution with the DMSO as the control, and the
LD50 = 159 µM (n=3). The fraction viability was calculated by the average, and the orange
curve represents the fitted curve for this dose response curve.
The Median Lethal Dose of Temozolomide in Treating HL60 cells was 981 µM
As opposed to laromustine treatment, a 24 hr temozolomide treatment with
concentrations ranging from 0.244 µM to 62.5 µM yielded very little cell death. Cell viability
started to significantly decrease at concentrations above 125 µM. The lethal dose of 1000 µM
was established (Figure 9). For the synergism analyses, temozolomide concentrations of
1000 µM and 100 µM were selected as lethal and near-lethal doses, respectively.
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Figure 10. The temozolomide dose response curve for HL60 cells seeded at the
concentrations of 25,000 cells/well, in 384-well plates. Concentrations of the drugs ranged
from 0.24 to 2,000 µM in a two-fold serial dilution with DMSO as the control, and the LD50 =
981 µM (n=3). The fraction viability was calculated by the average, and the orange curve
represents the fitted curve for this dose response curve.
For both laromsutine and temozolomide, concentrations that could be applied for the
chemical genetic screen were estimated from Figure 9 and Figure 10. The concentrations
selected should induce some but not all the cell death. A high concentration would impede
the observation for synergism effects, and a low concentration might not be able to yield any
observable changes. Initially, 20 µM laromustine and 100 µM temozolomide were chosen,
and they were compared with 200 µM laromustine and 1000 µM temozolomide, which were
10x the chosen concentrations. Those 10x concentrations were expected to induce a
significant amount of cell death. Different concentrations of laromustine and temozolomide
were tested for luminescence after 24 hr of treatment. The control groups (treated by DMSO)
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worked as expected. For laromustine, a sharp decrease in cell viability was observed when
the concentration increased from 20 µM to 200 µM (Figure 11). As expected, a concentration
of 200 µM resulted in significant loss of HL60 cell viability. A 20 µM concentration showed a
luminescence signal lower than that of the control but still high enough to show the potential
influence of the other compound. Thus, concentrations of 20 µM and 50 µM laromustine were
selected for the synergism experiments. As for temozolomide, the luminescent signal
generated by cells exposed to 1000 µM temozolomide was significantly lower than that of
cells treated with 100 µM temozolomide (Figure 11). However, the 100 µM treatment
produced a luminescent signal higher than the controls. Therefore, 200 µM and 500 µM
temozolomide were chosen to be tested with laromustine.

Figure 11. HL60 cells were seeded at the concentration of 40,000 cells/well with different
compound concentrations, including DMSO as the control. Data were analyzed after 24 hr
for average luminescence (n=8).
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Laromustine (50µM) and Temozolomide (200µM) Worked Synergistically to Induce HL60 Cell
Death
In order to test the optimization results of the chemical genetic screen, temozolomide
was tested for its synergistic effect with laromustine. Among all four combinations, cells
treated with 50 µM laromustine and 500 µM temozolomide showed some synergistic toxicity
(Figure 12.A). This result was significant relative to the control DMSO group. The other
combinations also showed signal results lower than that of the control group, but those
results looked more additive than synergistic. However, the results from Figure 12.A were
not repeatable at 24 hr post treatment. The reason for this observation might be that the
long treatment period made the cells continue to grow under pressure. In another
experiment (Figure 12.B), cells were treated for only 12 hr. As shown in Figure 12.B, the
combination of 50 µM laromustine and 500 µM temozolomide still demonstrated some
synergism.
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A

B

Figure 12. Cell viability at different concentrations of temozolomide (T), laromustine (L),
and their combinations, as compared to the control group with the treatment of 2% DMSO.
A showed the light signal detected after 24 hr of treatment (n=8). B showed the
luminescence signal measured after 12 hr of treatment (n=4).
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Discussion
As a result of these experiments, the optimal seeding density for HL60 cells was
determined to be 25,000 – 40,000 cells/well in a 24-well plate, with 2% DMSO as the control.
Those seeding densities showed stable luminescence signal and could accurately reflect the
number of viable cells in each well. Then, the cells should be transferred to the 384-well
plates, 25 µL/well, to be measured for luminescence signal by the CellTiter-Glo reagent after
12 hours or 24 hours of treatment. Though in the experiment with temozolomide, the
synergism effect was not able to be observed again at 24 hr post treatment, both 12 hr and
24 hr should be considered in the next step experiments. When testing the combined effects
between laromustine and temozolomide, some synergism was observed between 50 µM
laromustine and 500 µM temozolomide. When being tested for the chemical genetic screen,
50 µM of laromustine was selected as the optimal concentration.
At this point, all the conditions (cell seeding density, treatment period, and
laromustine concentration) for the chemical genetic screen were optimized. This project
should be able to move to the screening process. Before that, the cytotoxicity for the
combination of laromustine and Olaparib, the PARP inhibitor, should be tested. The project
is going to collaborate with Professor Robert Wheeler at the University of Maine, Orono to
test laromustine with the collection of 450 FDA-approved compounds. Compounds and
cellular targets identified from this chemical genetic screen will be verified individually and
independently.
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